FDA Gives the Nod to 'Risperdal' For Use in Autistic Children

by Medindia Content Team on  October 10, 2006 at 8:33 AM Drug News   - G J E 4
FDA Gives the Nod to 'Risperdal' For Use in Autistic Children
The Food and drug administration has given the go-ahead for a schizophrenia drug to be used in management of autism in children. The drug in question, Johnson & Johnson's 'Risperdal', holds promise in effectively managing irritability, aggression, self-injury and temper tantrums that might show up in autistic children.

Risperdal, an oral drug, holds a niche position as Johnson & Johnson's acclaimed product and has been in circulation since 1993, for treatment of schizophrenia. The approval by the FDA follows a detailed study undertaken in two phases, with 156 autistic patients aged 5 to 16. The study spanning 16 weeks involved administration of either Risperdal or a placebo to the study subjects. The finding revealed that patients who had consumed Risperdal portrayed measurable improvements in behavioral symptoms as compared to subjects who had consumed the placebo.

Further, Johnson & Johnson have communicated that Risperdal is not the answer for main autism symptoms that deal with communication problems and social behavior. Nevertheless, the drug shows positive results in 'treating the associated behavioral disturbances that can interfere with school, learning and family life.'

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All

More News on: